NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 230 filers reported holding NEKTAR THERAPEUTICS in Q3 2022. The put-call ratio across all filers is 0.14 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $32,000 | -45.8% | 10,001 | -35.8% | 0.00% | – |
| Q2 2022 | $59,000 | -39.2% | 15,579 | -13.4% | 0.00% | – |
| Q1 2022 | $97,000 | -74.8% | 17,999 | -36.9% | 0.00% | – |
| Q4 2021 | $385,000 | -32.1% | 28,516 | -9.7% | 0.00% | -100.0% |
| Q3 2021 | $567,000 | +19.6% | 31,576 | +14.3% | 0.00% | – |
| Q2 2021 | $474,000 | -18.4% | 27,615 | -4.9% | 0.00% | -100.0% |
| Q1 2021 | $581,000 | +27.7% | 29,050 | +8.5% | 0.00% | – |
| Q4 2020 | $455,000 | +2.9% | 26,785 | +0.5% | 0.00% | -100.0% |
| Q3 2020 | $442,000 | -29.5% | 26,665 | -1.5% | 0.00% | 0.0% |
| Q2 2020 | $627,000 | +36.9% | 27,067 | +5.5% | 0.00% | 0.0% |
| Q1 2020 | $458,000 | -18.8% | 25,652 | -1.8% | 0.00% | 0.0% |
| Q4 2019 | $564,000 | +26.2% | 26,135 | +6.5% | 0.00% | 0.0% |
| Q3 2019 | $447,000 | -79.1% | 24,532 | -59.2% | 0.00% | -66.7% |
| Q2 2019 | $2,142,000 | +48.5% | 60,189 | +40.2% | 0.00% | +50.0% |
| Q1 2019 | $1,442,000 | +4.9% | 42,919 | +2.6% | 0.00% | 0.0% |
| Q4 2018 | $1,375,000 | -61.0% | 41,825 | -27.8% | 0.00% | -60.0% |
| Q3 2018 | $3,530,000 | +6.7% | 57,908 | -14.5% | 0.01% | -16.7% |
| Q2 2018 | $3,308,000 | -66.2% | 67,746 | -26.5% | 0.01% | -66.7% |
| Q1 2018 | $9,792,000 | +19.6% | 92,148 | -43.7% | 0.02% | +20.0% |
| Q4 2017 | $8,190,000 | +166.8% | 163,617 | +27.9% | 0.02% | +150.0% |
| Q3 2017 | $3,070,000 | +23.7% | 127,900 | +0.7% | 0.01% | +20.0% |
| Q2 2017 | $2,482,000 | -9.4% | 126,950 | +8.7% | 0.01% | -16.7% |
| Q1 2017 | $2,740,000 | +51.0% | 116,760 | -21.1% | 0.01% | +20.0% |
| Q4 2016 | $1,815,000 | -5.6% | 147,960 | +32.2% | 0.01% | 0.0% |
| Q3 2016 | $1,923,000 | +59.5% | 111,904 | +32.0% | 0.01% | +25.0% |
| Q2 2016 | $1,206,000 | +6.1% | 84,761 | +2.5% | 0.00% | 0.0% |
| Q1 2016 | $1,137,000 | -16.0% | 82,696 | +3.0% | 0.00% | -20.0% |
| Q4 2015 | $1,353,000 | +60.1% | 80,280 | +4.2% | 0.01% | +66.7% |
| Q3 2015 | $845,000 | -10.5% | 77,060 | +2.1% | 0.00% | -25.0% |
| Q2 2015 | $944,000 | +34.1% | 75,460 | +17.9% | 0.00% | +33.3% |
| Q1 2015 | $704,000 | +96.6% | 64,010 | +177.1% | 0.00% | +50.0% |
| Q4 2014 | $358,000 | – | 23,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Camber Capital Management LP | 2,000,000 | $67,200,000 | 3.35% |
| First Light Asset Management, LLC | 763,403 | $25,650,000 | 3.33% |
| BRIDGER MANAGEMENT, LLC | 1,238,489 | $41,613,000 | 3.29% |
| Rhenman & Partners Asset Management AB | 734,445 | $24,677,000 | 2.89% |
| BB BIOTECH AG | 2,020,676 | $67,895,000 | 1.71% |
| Gs Investments, Inc. | 54,200 | $1,821,120,000 | 1.43% |
| Artal Group S.A. | 900,000 | $30,240,000 | 1.24% |
| Cormorant Asset Management, LP | 500,000 | $16,800,000 | 1.14% |
| TOBAM | 640,547 | $21,522,000 | 1.09% |
| Bellevue Group AG | 430,026 | $14,449,000 | 0.80% |